Adicet Bio, Inc. Increase (Decrease) in Contract with Customer, Liability
Adicet Bio, Inc. (ACET) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2024-03-19
- Adicet Bio, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was $0.00.
- Adicet Bio, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was $0.00.
- Adicet Bio, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2022-12-31 was $0.00.
- Adicet Bio, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2022-09-30 was $0.00.
- Adicet Bio, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
- Adicet Bio, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$4.80M.
- Adicet Bio, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$9.18M.
- Adicet Bio, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was -$7.90M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $0.00 10-K · filed 2024-03-19 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $0.00 derived: sum of 3 quarters · filed 2024-03-19 | -$4.80M 10-K · filed 2024-03-19 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | -$4.80M 10-Q · filed 2023-11-08 | -$10.09M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$4.80M 10-Q · filed 2023-08-09 | -$10.09M derived: sum of 3 quarters · filed 2023-08-09 | -$13.15M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$4.80M 10-Q · filed 2023-05-09 | -$10.09M derived: sum of 2 quarters · filed 2023-05-09 | -$13.15M derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$8.34M derived: sum of 2 quarters · filed 2023-03-15 | -$9.18M 10-K · filed 2023-03-15 | |
| 2021-09-30 | -$3.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$3.89M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | -$833.00K 10-Q · filed 2022-08-10 | |||
| 2020-12-31 | -$5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$8.44M derived: sum of 2 quarters · filed 2022-03-15 | -$5.90M derived: sum of 3 quarters · filed 2022-03-15 | -$7.90M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$3.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$493.00K derived: sum of 2 quarters · filed 2021-11-10 | -$2.49M 10-Q · filed 2021-11-10 | -$4.46M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $2.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $535.00K 10-Q · filed 2021-08-12 | -$1.43M derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$2.00M 10-Q · filed 2021-05-17 | -$3.97M derived: sum of 2 quarters · filed 2021-05-17 | ||
| 2019-12-31 | -$1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$995.00K 10-K · filed 2021-03-12 | ||
| 2019-09-30 | $974.00K 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | -$3.18M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |